Every peptide we use, including BPC-157, is sourced exclusively from licensed compounding pharmacies that produce human-grade medications
AE leading to drug discontinuation were observed in 16% of participants with the 12 mg dose, but the overall incidence of SAE was low (up to 6-8%)
However, we can glean some insights from studies of cagrilintide with other GLP-1 agonists and the individual safety profiles of these medications: Cagrilintide has shown a favorable safety profile in clinical trials, with most adverse events being mild to moderate in severity
(17, 18) This can lead to dehydration, which, in turn, causes dizziness and lightheadedness
Below are some of the most common mistakes buyers makeand how they can be avoided
European Journal of Clinical Nutrition, 72 (1), 105